INFI Projected Dividend Yield
Infinity Pharmaceuticals Inc ( OTCBB : INFI )Infinity Pharmaceuticals is a clinical-stage biopharmaceutical company. Co. is focused on advancing eganelisib (IPI-549), an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma. The preclinical findings indicate that eganelisib may have the potential to treat various solid tumors and represents an additive or synergistic approach to restoring anti-tumor immunity in combination with other immunotherapies such as checkpoint inhibitors. Further, preclinical studies showed that eganelisib inhibits the regrowth of tumors that can occur following treatment with chemotherapy. 20 YEAR PERFORMANCE RESULTS |
INFI Dividend History Detail INFI Dividend News INFI Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |